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dramatically increased during irradiation alone; while DS 
treatment significantly inhibited the radiation-induced 
increase of IL-1β, however, no systematical effect of DS 
on the expression of NF-κB was observed. The hypoxia 
markers HIF-1α and GLUT-1 showed a progressive increase 
during irradiation alone that, however, was also not 
influenced by DS. 
Conclusion  
DS has a significant mucoprotective effect during daily 
fractionated radiotherapy. This is neither based on 
stimulation of epithelial proliferation nor on modulation 
of radiation-induced hypoxic changes. In contrast, 
increased expression of epithelial junctions and thereby 
strengthened epithelial anchorage and/or reduced or 
modulated inflammatory processes appear to be the 
biological mechanisms underlying the observed 
mucoprotective effect. 
  
 
Symposium: Brachytherapy pays  
 
 
SP-0122  Introducing the Brachy-HERO initiative 
L.T. Tan1 
1Addenbrooke's Hospital - Oncology Centre University of 
Cambridge, Cambridge, United Kingdom  
The ESTRO HERO project (Health Economics in Radiation 
Oncology) has the overall aim to develop a knowledge base 
and a model for health economic evaluation of radiation 
treatments at the level of individual European countries. 
The project deals with four dimensions organised in 
different work-packages: availability, resource needs, 
cost-accounting and economic evaluation. 
This talk will introduce the Brachy-HERO project which 
seeks to extend the aims of the HERO project to the field 
of brachytherapy. Preliminary data on brachytherapy use 
and resource availability in Europe will be presented.   
 
SP-0123  Review of health related quality of life 
measures with brachytherapy and application to QALY 
for economic evaluation 
H. Kim1 
1University of Pittsburgh Cancer Institute, Radiation 
Oncology, Pittsburg- PA, USA 
 
Patient reported outcome using  health related quality of 
life (HRQOL) has become an increasingly important part of 
assessing therapeutic choices especially in cancer 
treatments. 
The improvement in HRQOL is one of main economic 
benefits of treatment and it is incorporated in economic 
evaluation.  
In this talk, the speaker will review the followings: 
 
1.  General overview of HRQOL 
1) Types of quality of life scales, 2) How the utility score 
for a particular health state is determined, 3) How utility 
values are applied to treatment effectiveness. 
2. Utility values related to brachytherapy 
3. Literature review of economic evaluation for various 
cancers treated with brachytherapy 
1) Partial breast irradiation brachytherapy, 2) Prostate 
HDR brachytherapy, 3) Gynecological HDR brachytherapy, 
4) Eye plaque brachytherapy 
4. Limitations of current utility values in brachytherapy 
       
SP-0124  Optimal utilisation of brachytherapy in Europe 
-can it be measured? 
J.M. Borras1 
1Institut Català d'Oncologia, Cancer plan, L'Hospitalet de 
Llobregat, Spain 
 
Mssost of the approaches applied in order to assess the 
need for radiotherapy have been focused on external 
radiotherapy. From this perspective, there is a gap in the 
evaluation of the potential need for brachytherapy in 
European countries. Three approaches have been used for 
planning radiotherapy: expert opinion, benchmarking and 
evidence based assessment of the indications for 
treatment. Benchmarking is based on the selection of one 
territory with appropriate level of resources for therapy 
and accepted as a reference for the experts, which could 
be used as a comparison for the rest of territories. Usually, 
the reference territory has data from a population based 
cancer registry in order to make sure that all cancer 
patients are included in the comparison. Evidence based 
indications review the evidence, using clinical guidelines 
and primary evidence, in order to provide the optimal 
treatment percentage of cases that would receive 
radiotherapy, as shown by the CCORE model. Both 
approaches have advantages and problems that will be 
discussed with a focus on brachytherapy. 
The epidemiological data required to assess the optimal 
use of brachytherapy is available for some countries in 
Europe but there are good estimates that allow to provide 
data for most countries in Europe, as it has been shown in 
th ESTRO-HERO project carried out recently for external 
radiotherapy. Data on incidence and stage at diagnosis for 
the most frequent tumour sites are available, from 
population based cancer registries. In addition to the 
epidemiological data, the potential indications for 
brachytherapy are also required. The consensus over the 
evidence for brachytherapy indications and the potential 
factors explaining the gap between optimal and actual use 
will be discussed, using prostate cancer as a case study. 
The epidemiological approach proposed to assess the need 
for brachytherapy is aligned to the National cancer plan 
requirements and could be an useful input of data to 
assess the gap in the actual utilization of this therapeutic 
strategy.    
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There is little evidence to guide treatment in elderly 
patients with muscle invasive bladder cancer (MIBC). We 
aimed to assess the efficacy and tolerability of concurrent 
radical radiotherapy with gemcitabine radiosensitisation 
(GemX) in elderly patients with MIBC and correlate 
outcomes to those from the bladder carbogen and 
nicotinamide (BCON) phase III clinical trial.  
Material and Methods  
Data was retrospectively analysed from patients who 
received GemX between May 2010 and December 2014 
from two oncology centres in the United Kingdom. Elderly 
was defined as aged ≥75 at the start of GemX. Following 
transurethral resection of bladder tumour, where 
appropriate, patients received neo-adjuvant platinum-
based chemotherapy followed by radiotherapy (50-55 
Gy/20 fractions) concurrently with weekly gemcitabine 
(100 mg/m2). A separate, elderly-specific analysis was 
performed in the BCON cohort. Overall survival (OS), 
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disease specific survival (DSS) and local progression free 
survival (LPFS) were evaluated using Kaplan-Meier 
methodology and Cox proportional hazards regression. 
Results  
Out of 167 patients, 61 (36.5%) were elderly with a median 
age of 78 years (range 75-89). Elderly patients had worse 
performance status (p=0.02) and co-morbidities (p=0.03). 
A similar proportion of patients received planned dose 
radiotherapy in both groups (p=0.26), although fewer 
elderly patients received all four cycles of concurrent 
chemotherapy (p=0.014) due to toxicity. With a median 
follow-up time of 38 months for those alive; hazard ratios 
(HR) comparing younger and elderly for OS, DSS and LPFS 
were 1.04 (95% CI 1.00-1.08; log-rank p=0.068), 1.00 (95% 
CI 0.95-1.04; log-rank p=0.916) and 1.00 (95% CI 0.95-1.04; 
log-rank p=0.899) respectively (Figure 1). Late grade 3/4 
genitourinary (GU) or gastrointestinal (GI) toxicity was 
reported in three patients in the younger group and none 
in the elderly group. Age was not a significant prognostic 
factor in univariate analysis. In the CON arm of the BCON 
trial, elderly patients demonstrated similar LPFS (HR 1.03, 
95% CI 0.99-1.06; log-rank p=0.145), but worse OS (HR 
1.05, 95% CI 1.02-1.08; log-rank p=0.002) compared to 
their younger counterparts. Overall survival and LPFS in 
elderly patients were comparable between CON and GemX 
(HR 1.13, 95% CI 0.69-1.85; log-rank p=0.616 and HR 0.85, 
95% CI 0.41-1.74; log-rank p=0.659 respectively) (Figure 
2).  
 
 
 
 
 
Conclusion  
Radiosensitisation is safe and effective and should be 
considered for fit elderly patients with MIBC. 
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Purpose or Objective  
To conduct a central pathology review within a 
randomized clinical trial on salvage radiation therapy (RT) 
in the presence of biochemical recurrence after 
prostatectomy to assess whether this results in shifts of 
histopathological prognostic factors such as the Gleason 
Score. 
Material and Methods  
A total of 350 patients were randomized and specimens of 
279 (80%) of the patients were centrally reviewed by a 
dedicated genitourinary pathologist. The Gleason Score, 
tumor classification and resection margin status were 
reassessed and compared with the local pathology reports. 
Agreement was assessed using contingency tables and 
Cohen’s Kappa. Additionally, the association between 
other histopathological features (e.g. largest diameter of 
carcinoma) with rising PSA (up to 6 months after salvage 
RT) was investigated. 
Results  
There was good concordance between central pathology 
review and local pathologists for seminal vesicle invasion 
[pT3b: 91%; k=0.95 (95% CI 0.89, 1.00)], for extraprostatic 
extension [pT3a/b: 94%; k=0.82 (95% CI 0.75, 0.89)], and 
for positive surgical margin status [87%; k=0.7 (95% CI 
0.62, 0.79)]. Agreement was lower for Gleason score [78%; 
k=0.61 (95% CI 0.52, 0.70)]. The median largest diameter 
of carcinoma was 16 mm (range, 3–38 mm). A total of 49 
patients (18%) experienced a rising PSA after salvage RT. 
Largest diameter of carcinoma [odds ratio (OR): 2.04 (95% 
Confidence interval (CI): 1.30, 3.20); p = 0.002], resection 
margin status [OR: 0.36 (95% CI: 0.18, 0.72); p = 0.004] 
